Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Standard-dose RT with concurrent chemo found superior for unresectable NSCLC

Key clinical point: Overall survival data support 60 Gy of radiation with concurrent chemotherapy as standard of care for unresectable stage III NSCLC.

Major finding: Compared with high-dose RT, standard-dose RT yielded better median overall survival (28.7 vs. 20.3 months; P = .0072), 5-year overall survival (32.1% vs. 23%; P = .007), and 5-year progression-free survival (18.3% vs. 13%; P = .055).

Study details: Update of a phase 3 randomized controlled trial among 496 patients with unresectable stage III NSCLC comparing standard-dose RT (60 Gy) vs. high-dose RT (74 Gy) with concurrent chemotherapy, as well as cetuximab vs. no cetuximab (RTOG 0617 trial).

Disclosures: Dr. Bradley disclosed having a consulting or advisory role with AstraZeneca. The trial was supported by the National Cancer Institute and Eli Lilly.

Citation:

Bradley JD et al. J Clin Oncol. 2019 Dec 16. doi: 10.1200/JCO.19.01162.